I am a urologic cancer specialist. My research focuses on elucidating mechanisms of therapy resistance in bone metastatic urologic cancers using patient-derived xenograft (PDX) models and 3D in vitro models. My expertise in genome-wide analyses of prostate cancer tumors and primary patient-derived tumor models focuses on translating next generation genomics on prostate cancers into practical applications and novel therapies to improve and hopefully eventually transform patient care.